MA28104A1 - Sel antagonistes de ccr-2 - Google Patents

Sel antagonistes de ccr-2

Info

Publication number
MA28104A1
MA28104A1 MA28957A MA28957A MA28104A1 MA 28104 A1 MA28104 A1 MA 28104A1 MA 28957 A MA28957 A MA 28957A MA 28957 A MA28957 A MA 28957A MA 28104 A1 MA28104 A1 MA 28104A1
Authority
MA
Morocco
Prior art keywords
salt
ccr
antagonists
succinate salt
methoxytetrahydro
Prior art date
Application number
MA28957A
Other languages
English (en)
Inventor
Mark Jensen
Robert Larsen
Daniel Richard Sidler
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of MA28104A1 publication Critical patent/MA28104A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention fournit une synthèse efficace pour la préparation de ((1R,3S)-3-isopropyl-3-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé et son sel succinate. La présente invention fournit en plus une synthèse efficace pour la préparation des intermédiaires (3R)-3-méthoxytétrahydro-4H-pyran-4-one; acide (1S,4S)-4-(2,5-diméthyl- 1H-pyrrol- 1-yl)-1-isopropylcyclopent-2-ene-1-carboxylique; et 3-(trifluorométhyl)-5,6,7,8-tétrahydro-1,6-naphtydirine; et pour la préparation du précurseur (3S,4S)-N-((1S,4S)-4-isopropyl-4-{[3-(trifluorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl] carbonyl} cyclopent-2-en-1-yl)-3-méthoxytétrahydro-2H-pyran-4-amine. L'invention concerne en outre les propriétés supérieures du sel succinate de ((1R,3S)-3-isopropyl-3-{[3-(trifiuorométhyl)-7,8-dihydro-1,6-naphtyridin-6(5H)-yl]carbonyl}cyclopentyl) [(3S,4S)-3-méthoxytétrahydro-2H-pyran-4-yl] aminé.
MA28957A 2003-10-27 2006-04-24 Sel antagonistes de ccr-2 MA28104A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51473503P 2003-10-27 2003-10-27

Publications (1)

Publication Number Publication Date
MA28104A1 true MA28104A1 (fr) 2006-08-01

Family

ID=34572774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28957A MA28104A1 (fr) 2003-10-27 2006-04-24 Sel antagonistes de ccr-2

Country Status (21)

Country Link
US (1) US7473696B2 (fr)
EP (1) EP1682135B1 (fr)
JP (1) JP4542550B2 (fr)
KR (1) KR20060101476A (fr)
CN (1) CN1870998B (fr)
AT (1) ATE517622T1 (fr)
AU (1) AU2004287416C1 (fr)
BR (1) BRPI0415836A (fr)
CA (1) CA2543201C (fr)
CO (1) CO5690606A2 (fr)
EC (1) ECSP066524A (fr)
IL (1) IL175009A0 (fr)
IS (1) IS8400A (fr)
MA (1) MA28104A1 (fr)
MX (1) MXPA06004647A (fr)
NO (1) NO20062377L (fr)
NZ (1) NZ546447A (fr)
RU (1) RU2317295C1 (fr)
UA (1) UA81365C2 (fr)
WO (1) WO2005044264A1 (fr)
ZA (1) ZA200602752B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030582A1 (en) * 2002-04-29 2006-02-09 Demartino Julie Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004050024A2 (fr) 2002-11-27 2004-06-17 Incyte Corporation Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine
WO2004082616A2 (fr) * 2003-03-18 2004-09-30 Merck & Co. Inc. Modulateurs d'amide tetrahydropyranyl cyclopentyl heterocylique de l'activite des recepteurs des chimiokines
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2
CA2550596C (fr) 2003-12-18 2011-03-15 Incyte Corporation Derives 3-cycloalkylaminopyrrolidine utilises en tant que modulateurs des recepteurs de chimiokine
CN1950085A (zh) 2004-05-11 2007-04-18 因赛特公司 作为趋化因子受体调节剂的3－(4－杂芳基环己基氨基)环戊烷羧酰胺
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MX2009005252A (es) 2006-11-17 2009-05-28 Abbott Lab Aminopirrolidinas como antagonistas del receptor de quimiocina.
US20090076065A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk-0812
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012125663A2 (fr) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés d'amino cyclopentane substitués par cyclohexane en tant qu'antagonistes utiles de ccr2
WO2013149376A1 (fr) 2012-04-02 2013-10-10 Abbott Laboratories Antagonistes de récepteurs de chimiokines
EP2962691A4 (fr) 2013-02-28 2016-08-31 Santen Pharmaceutical Co Ltd Agent de prévention ou de traitement de maladies de la partie postérieure de l' il contenant un dérivé de tétrahydropyranylaminocyclopentylcarbonyltétrahydropyridopyridine en tant que principe actif
RU2726206C2 (ru) 2015-05-21 2020-07-09 Кемосентрикс, Инк. Модуляторы ccr2
EP3687525B1 (fr) 2017-09-25 2025-10-29 ChemoCentryx, Inc. Polythérapie utilisant un antagoniste du récepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
US20190269664A1 (en) 2018-01-08 2019-09-05 Chemocentryx, Inc. Methods of treating solid tumors with ccr2 antagonists
CN112105353B (zh) 2018-01-08 2024-04-19 凯莫森特里克斯股份有限公司 Ccr2拮抗剂治疗实体瘤的方法
CN112341350A (zh) * 2020-10-19 2021-02-09 江苏威奇达药业有限公司 酶法拆分γ-内酰胺后副产物的处理方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
JPH09291034A (ja) * 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
RU2174123C2 (ru) * 1996-10-28 2001-09-27 Новартис Аг Производные 8-арил-1,7-нафтиридина и фармацевтическая композиция, обладающая противовоспалительной активностью
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2787790A1 (fr) * 1998-12-23 2000-06-30 Sanofi Sa Procede de preparation du (r)-(+)-3-{1[2-(4-benzoyl-2-(3,4- difluorophenyl)morpholin-2-yl)ethyl]-4-phenylpiperidin-4-yl} -1,1-dimethyluree, de ses sels, solvats et/ou hydrates
US6500844B1 (en) * 1999-06-11 2002-12-31 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
WO2002013824A1 (fr) * 2000-08-17 2002-02-21 Merck & Co., Inc. Modulateurs cyclopentyles de l'activite du recepteur de la chimiokine
MXPA03004714A (es) * 2000-11-28 2003-08-19 Pfizer Prod Inc Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
IL161326A0 (en) * 2001-11-29 2004-09-27 Pfizer Prod Inc Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof
CN1608062A (zh) * 2001-12-12 2005-04-20 辉瑞产品公司 E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
JP3780291B2 (ja) * 2002-04-29 2006-05-31 メルク エンド カムパニー インコーポレーテッド テトラヒドロピラニルシクロペンチルテトラヒドロピリドピリジン系のケモカイン受容体活性調節剤
CA2483843A1 (fr) * 2002-04-29 2003-11-13 Merck & Co. Inc. Modulateurs de l'activite des recepteurs des chimiokines a base de tetrahydropyranyl cyclopentyl tetrahydroisoquinoline
AR045875A1 (es) * 2003-10-27 2005-11-16 Merck & Co Inc Procedimiento para la preparacion del antagonista ccr-2

Also Published As

Publication number Publication date
WO2005044264A1 (fr) 2005-05-19
NO20062377L (no) 2006-05-24
ATE517622T1 (de) 2011-08-15
NZ546447A (en) 2009-02-28
ECSP066524A (es) 2006-10-10
CN1870998A (zh) 2006-11-29
EP1682135A1 (fr) 2006-07-26
JP2007509940A (ja) 2007-04-19
AU2004287416C1 (en) 2010-09-09
IS8400A (is) 2006-04-06
EP1682135B1 (fr) 2011-07-27
AU2004287416A1 (en) 2005-05-19
MXPA06004647A (es) 2006-06-27
JP4542550B2 (ja) 2010-09-15
IL175009A0 (en) 2006-08-20
AU2004287416B2 (en) 2009-11-19
UA81365C2 (en) 2007-12-25
CO5690606A2 (es) 2006-10-31
CN1870998B (zh) 2010-10-20
CA2543201C (fr) 2010-12-21
CA2543201A1 (fr) 2005-05-19
EP1682135A4 (fr) 2009-11-25
RU2317295C1 (ru) 2008-02-20
US7473696B2 (en) 2009-01-06
KR20060101476A (ko) 2006-09-25
US20070135474A1 (en) 2007-06-14
BRPI0415836A (pt) 2007-01-02
ZA200602752B (en) 2007-08-29

Similar Documents

Publication Publication Date Title
EP1682135A4 (fr) Sel antagoniste de ccr-2
PA8637601A1 (es) Compuestos moduladores de la actividad de c-kit y usos de los mismos
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d&#39;utilisation
BR0014352A (pt) Cetoenóis espirocìclicos substituìdos por trifluormetila
DE60312701D1 (de) Darstellung von 1h-imidazoä4,5-cüchinolin-4-aminen über neue 1h-imidazoä4,5-cüchinolin-4-cyano- und 1h-imidazoä4,5-cüchinolin-4-carboxamid intermediate
WO2005037198A3 (fr) Preparation d&#39;azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
WO2007013896A3 (fr) Composes modulant l&#39;activite de c-kit et c-fms et utilisations
EP1675552A4 (fr) Preparation d&#39;azabenzimidazoles 1,6-disubstitues comme inhibiteurs de kinases
WO2005040169A3 (fr) Composes heterocycliques fusionnes
WO2001066534A3 (fr) Antagonistes du recepteur d&#39;histamine-3 diamino cycliques et bicycliques
PT1622569E (pt) Derivados de aza espiro alcanos como inibidores de metaloproteases
GEP20074210B (en) Tropane derivatives as ccr5 modulators
RU2009140095A (ru) Гетероарильные производные
WO2005049561A3 (fr) Procedes de preparation d&#39;un nouveau derive de bleu de methylene
WO2004106340A3 (fr) Derives substitues en 4 de pyrazolo[3,4-d]pyrimidine et pyrrolo[2,3-d]pyrimidine et utilisations associees
IL175958A0 (en) Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
MXPA05008183A (es) Proceso para preparar pirrolotriazina como inhibidores de cinasa.
WO2005044795A8 (fr) Procede d&#39;elaboration d&#39;antagoniste vis-a-vis du ccr-2
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
AU2003274307A1 (en) 5-ht 1b/1d receptor agonists for the treatment of headache resulting from administering an endothelin receptor antagonist
IS7492A (is) Lyfjablöndu uppskriftir, sem innifela melantónín
DE60008400D1 (de) Triazolopyrimidinderivate
MX2010001602A (es) &#34;compuestos de 2-(2-oxoindolin-3-iliden)metil-5-(2-hidroxi-3-morfo lin-4-il-propil)-6,7-dihidro-1h-pirrol[3,2-c]pirridin-4(5h)-ona y su uso como inhibidores de proteína quinasa&#34;.
EP1786815A4 (fr) Composes spiro et procedes pour la modulation de l&#39;activite de recepteur de chimiokine
DE602004009962D1 (de) Verfahren zur herstellung von substituierten 5-aminopyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidinen